SER (Serina Therapeutics) Debt-to-Equity: 0.18 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SER Serina Therapeutics Inc SER
12 GF Score
Price $1.95
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics Debt-to-Equity?

Serina Therapeutics SER -6.70% 12 Debt-to-Equity is 0.18 as of Mar. 2026. GuruFocus rates SER with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 966 Biotechnology companies, Serina Therapeutics ranks worse than 51.55% on this metric.

Serina Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. Serina Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $3.17 Mil. Serina Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $17.63 Mil. Serina Therapeutics's debt to equity for the quarter that ended in Mar. 2026 was 0.18.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Serina Therapeutics's Debt-to-Equity or its related term are showing as below:

SER' s Debt-to-Equity Range Over the Past 10 Years
Min: -84.92   Med: -0.05   Max: 1.73
Current: 0.18

During the past 5 years, the highest Debt-to-Equity Ratio of Serina Therapeutics was 1.73. The lowest was -84.92. And the median was -0.05.

SER's Debt-to-Equity is ranked worse than
51.55% of 966 companies
in the Biotechnology industry
Industry Median: 0.16 vs SER: 0.18

Serina Therapeutics  (AMEX:SER) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Serina Therapeutics Debt-to-Equity Related Terms

Serina Therapeutics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics Debt-to-Equity Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
-0.01 -0.05 -0.11 0.42 -84.92

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.10 1.73 -84.92 0.18

SER vs NRSN, IGC, PVCT: Debt-to-Equity Comparison

For the Biotechnology subindustry, Serina Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Serina Therapeutics Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Debt-to-Equity falls into.


SER
12GF Score
Serina Therapeutics Inc SER
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Serina Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 3.142) / -0.037
=-84.92

Serina Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 3.169) / 17.628
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.18 mean?
Serina Therapeutics (SER) has a Debt-to-Equity of 0.18 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Serina Therapeutics and its competitors. According to the industry distribution chart, Serina Therapeutics ranks #498 out of 966 companies in the Biotechnology industry, placing it in the top 51.6%.
Is Serina Therapeutics' Debt-to-Equity too high?
Serina Therapeutics' current Debt-to-Equity is 0.18. The Biotechnology industry median Debt-to-Equity is 0.16. Serina Therapeutics' value of 0.18 is 12.5% above this industry median. Based on the distribution chart, Serina Therapeutics ranks #498 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Serina Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' Debt-to-Equity compare to NRSN and IGC?
According to the Biotechnology industry distribution chart, Serina Therapeutics ranks #498 out of 966 companies for Debt-to-Equity. This places Serina Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Serina Therapeutics' value of 0.18 is 12.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Serina Therapeutics's current Debt-to-Equity of 0.18 is 12.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Serina Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Serina Therapeutics's current Debt-to-Equity is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (SER) has a current Debt-to-Equity of 0.18. The current Debt-to-Equity is 0.18 and 12.5% above the Biotechnology industry median of 0.16. Serina Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Serina Therapeutics (SER), the current Debt-to-Equity is 0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges 2BO:Germany
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
12GF Score

Get the complete analysis for SER

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.95
Price